Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week’s episode breaks down one of the most dangerous moments in biotech investing, when a company appears to “de-risk” after positive data and the market starts treating the story as inevitable. We dig into how that sense of certainty is often manufactured through narrative, how risk doesn’t disappear but instead quietly shifts into harder-to-see forms like durability, adoption, and reimbursement, and why investors consistently misprice these second-order problems. The discussion moves beyond trial results to focus on the structural reality of building a drug into a business, highlighting the gap between clinical success and real-world execution, and why the market is often most vulnerable right when it feels most confident.
📣🎙️ TODAY’S PODCAST:
[ 01:12 ] when that trial works
[ 01:30 ] manufactured certainty trap
[ 02:02 ] linear mental model failure
[ 02:33 ] relay race of risk
[ 03:31 ] durability risk reality
[ 05:29 ] compressing uncertainty playbook
[ 06:41 ] commercially ready illusion
[ 07:30 ] risk substitution game
[ 08:49 ] reimbursement risk wall
[ 10:00 ] adoption friction bottleneck
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
